Key result
Dopamine stimulation of D4.7 variants showed a twofold reduced potency to inhibit cAMP formation (EC50 ~37 nM) compared with D4.2 and D4.4 variants (EC50 ~16 nM).
The polymorphic repeat sequence in human dopamine D4 receptor variants causes only small changes in the ability to block cAMP production in vitro.
No takes yet. Share an insight, caveat, or question.
Modest D4.7 potency shifts should not yet alter practice; leaves open in vivo or clinical relevance of receptor variants.
Asghari et al. (1995) studied this question. Dopamine D4 receptor variants (D4.2, D4.4, D4.7) was evaluated on Inhibition of forskolin-stimulated cyclic AMP (cAMP) levels. Dopamine stimulation of D4.7 variants showed a twofold reduced potency to inhibit cAMP formation (EC50 ~37 nM) compared with D4.2 and D4.4 variants (EC50 ~16 nM).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: